Receptor tyrosine kinase inhibitors in cancer, By Amirhossein Ahmadi

Research

Title	Receptor tyrosine kinase inhibitors in cancer
Type	Article
Keywords	Targeted therapy · Immune therapy · RTK inhibitors · Drug resistance · Cancer therapy
Journal	CELLULAR AND MOLECULAR LIFE SCIENCES
DOI	https://doi.org/10.1007/s00018-023-04729-4
Researchers	Nasim Ebrahimi (First researcher) , Elmira Fardi (Second researcher) , Hajarossadat Ghaderi (Third researcher) , Sahar Palizdar (Fourth researcher) , Roya Khoram (Fifth researcher) , Reza Vafadar (Not in first six researchers) , Masoud Ghanaatian (Not in first six researchers) , Fatemeh Rezaei-tazangi (Not in first six researchers) , Payam Baziyar (Not in first six researchers) , Amirhossein Ahmadi (Not in first six researchers) , Michel Hamblin (Not in first six researchers) , Amir Reza Aref (Not in first six researchers)

Abstract

Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specifc proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential efects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.